AIMS: To develop a population pharmacokinetic model for lopinavir in combination with ritonavir, in which the interaction between both drugs was characterized, and in which relationships between patient characteristics and pharmacokinetics were identified. METHODS: The pharmacokinetics of lopinavir in combination with ritonavir were described using NONMEM (version V, level 1.1). First, ritonavir data were fitted to a previously developed model to obtain individual Bayesian estimates of pharmacokinetic parameters. Hereafter, an integrated model for the description of the pharmacokinetics of lopinavir with ritonavir was designed. RESULTS: From 122 outpatients 748 lopinavir and 748 ritonavir plasma concentrations were available for analysis. The interaction between the drugs was described by a time-independent inverse relationship between the exposure to ritonavir over a dosing-interval and the apparent clearance (CL/F) of lopinavir. The model parameters volume of distribution and absorption rate constant were 61.6 l (95% prediction interval (PI) 22.4, 83.7) and 0.564 h(-1) (95% PI 0.208, 0.947), respectively. The model yielded a theoretical value for the CL/F of lopinavir without ritonavir of 14.8 l h(-1) (95%PI 12.1, 20.1), which translates to a value of 5.73 l h(-1) in the presence of ritonavir. The only factor with significant effect on the pharmacokinetics was concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTI), which increased the CL/F of lopinavir by 39% (P < 0.001). CONCLUSIONS: We have developed a model that has defined a time-independent inverse relationship between the exposure to ritonavir and the CL/F of lopinavir, and provided an adequate description of the pharmacokinetic parameters for the latter. Concomitant use of the NNRTIs efavirenz and nevirapine increased the CL/F of lopinavir.
AIMS: To develop a population pharmacokinetic model for lopinavir in combination with ritonavir, in which the interaction between both drugs was characterized, and in which relationships between patient characteristics and pharmacokinetics were identified. METHODS: The pharmacokinetics of lopinavir in combination with ritonavir were described using NONMEM (version V, level 1.1). First, ritonavir data were fitted to a previously developed model to obtain individual Bayesian estimates of pharmacokinetic parameters. Hereafter, an integrated model for the description of the pharmacokinetics of lopinavir with ritonavir was designed. RESULTS: From 122 outpatients 748 lopinavir and 748 ritonavir plasma concentrations were available for analysis. The interaction between the drugs was described by a time-independent inverse relationship between the exposure to ritonavir over a dosing-interval and the apparent clearance (CL/F) of lopinavir. The model parameters volume of distribution and absorption rate constant were 61.6 l (95% prediction interval (PI) 22.4, 83.7) and 0.564 h(-1) (95% PI 0.208, 0.947), respectively. The model yielded a theoretical value for the CL/F of lopinavir without ritonavir of 14.8 l h(-1) (95%PI 12.1, 20.1), which translates to a value of 5.73 l h(-1) in the presence of ritonavir. The only factor with significant effect on the pharmacokinetics was concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTI), which increased the CL/F of lopinavir by 39% (P < 0.001). CONCLUSIONS: We have developed a model that has defined a time-independent inverse relationship between the exposure to ritonavir and the CL/F of lopinavir, and provided an adequate description of the pharmacokinetic parameters for the latter. Concomitant use of the NNRTIs efavirenz and nevirapine increased the CL/F of lopinavir.
Authors: Kristel M L Crommentuyn; Jan W Mulder; Rolf W Sparidans; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen Journal: Clin Infect Dis Date: 2004-04-01 Impact factor: 9.079
Authors: K M L Crommentuyn; H Rosing; L G A H Nan-Offeringa; M J X Hillebrand; A D R Huitema; J H Beijnen Journal: J Mass Spectrom Date: 2003-02 Impact factor: 1.982
Authors: Andrea De Luca; Francesco Baldini; Antonella Cingolani; Simona Di Giambenedetto; Richard M Hoetelmans; Roberto Cauda Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: Christoph Stephan; Nils von Hentig; Irene Kourbeti; Brenda Dauer; Manfred Mösch; Thomas Lutz; Stephan Klauke; Sebastian Harder; Michael Kurowski; Schlomo Staszewski Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: Tim R Cressey; Saik Urien; Edmund V Capparelli; Brookie M Best; Sudanee Buranabanjasatean; Aram Limtrakul; Boonsong Rawangban; Prapan Sabsanong; Jean-Marc Treluyer; Gonzague Jourdain; Alice Stek; Marc Lallemant; Mark Mirochnick Journal: J Antimicrob Chemother Date: 2014-09-25 Impact factor: 5.790
Authors: Natella Y Rakhmanina; John N van den Anker; Steven J Soldin; Ron H van Schaik; Nick Mordwinkin; Michael N Neely Journal: Ther Drug Monit Date: 2010-06 Impact factor: 3.681
Authors: R A B van Waterschoot; R ter Heine; E Wagenaar; C M M van der Kruijssen; R W Rooswinkel; A D R Huitema; J H Beijnen; A H Schinkel Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447